Publication | Open Access
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial
245
Citations
36
References
2022
Year
Efficacy and Mechanism Evaluation Programme (Medical Research Council and National Institute for Health Research, UK).
| Year | Citations | |
|---|---|---|
Page 1
Page 1